Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bleomycin + etoposide + platinum
- Development stage
- Phase 4
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intramuscular, Intravenous
01
Overview
Bleomycin + etoposide + platinum (commonly known as the BEP regimen) is a standard combination chemotherapy regimen consisting of bleomycin, etoposide, and a platinum agent (typically cisplatin). It is widely used as a first-line treatment for germ cell tumors, including testicular cancer and ovarian germ cell tumors, as well as gestational trophoblastic neoplasia and malignant sex cord-stromal tumors. Bleomycin is a glycopeptide antibiotic that induces DNA strand breaks; etoposide is a semisynthetic podophyllotoxin derivative that inhibits topoisomerase II; and cisplatin (or another platinum agent) is an alkylating-like agent that forms DNA crosslinks. Together, these agents synergistically inhibit DNA replication and transcription, leading to cell death in rapidly dividing cancer cells.
- Other names
- PEBPEB regimenadult BEPadult BEP regimenBEPBEP regimenbleomycin + etoposide + cisplatinbleomycin-etoposide-cisplatin regimenbleomycin-etoposide-Platinol regimenbleomycin/etoposide/platinum
02
Targets
DNATOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)
Beyond the preview
Go deeper on bleomycin + etoposide + platinum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bleomycin + etoposide + platinum.